Cognitive
therapy effective as drugs in long-term treatment of severe depression
By David F.
Salisbury
July 3, 2002
A type of therapy
that encourages severely depressed patients to challenge the judgments
and misperceptions that underlie their condition can be as effective
as medication over the long term.
That is the
conclusion of a new study conducted by researchers at Vanderbilt
University and the University of Pennsylvania comparing the relative
effectiveness of cognitive therapy and medication for the long-term
treatment of severe depression. The findings were discussed last
month at the annual conference of the American Psychiatric Association
in Philadelphia.
Cognitive
therapy was developed at Penn in the 1960's. Cognitive therapists
lead patients to explore harmful ideas such as "I'm a bad
person and don't deserve to have any fun" or "I'll never get that
job, so I won't even apply" and encourage them to test the
misperceptions that shape their negative feelings.
"In this study, we looked at depression somewhat differently than
prior studies," says Steven D. Hollon, professor of psychology at
Vanderbilt, who co-directed the investigation with Robert J. DeRubeis,
professor of psychology at Penn. "The question that has most often
been asked in studies is, 'What gets people better faster?' We asked,
'What will keep depression away over the long term?'"
Compared to past research on more severely depressed patients -
some depressed nearly enough to require hospitalization Hollon
and DeRubeis' study was unusually comprehensive in its size, 240
patients in Philadelphia and Nashville, and in its duration, 16
months.
|
|
The study involved a four-month period of acute treatment. Patients
who responded to therapy then discontinued treatment, except for an
occasional booster session. Those who responded to medications either
continued to take meds or were withdrawn onto a placebo pill. The
patients were then tracked for an additional year.
During the second phase of the study, 75 percent of patients who underwent
cognitive therapy avoided a relapse, compared to 60 percent of patients
who continued on medication and 19 percent of those withdrawn onto
a placebo pill.
"Statistically, both cognitive therapy and medication were more effective
than a placebo, and a brief course of cognitive therapy was better
than a similarly brief course of medication in the yearlong continuation
phase," DeRubeis says. "These results suggest that even after termination,
a brief course of cognitive therapy may offer enduring protection
comparable to that provided by ongoing medication."
Hollon, DeRubeis and colleagues also found that cognitive therapy
enjoys a long-term cost benefit compared to drugs. During the 16 months,
treatment with medication cost an average of $2,590, compared with
$2,250 for cognitive therapy. This gap grows with time, since antidepressants
must be administered continually to be effective.
"Some proponents of medication for severely depressed patients have
suggested that cognitive therapy is impractical on the basis of cost,"
DeRubeis says. "Our study indicates that isn't true, especially over
the long term.
"This will be a surprising, controversial finding for many psychiatric
professionals," he continues. "Most believe quite strongly in the
efficacy of medication, and psychiatric treatment guidelines call
unequivocally for medication in cases of severe depression."
DeRubeis and Hollon's colleagues in the study include Richard C. Shelton,
Ronald M. Solomon and Margaret L. Lovett of Vanderbilt's Department
of Psychiatry along with Jay D. Amsterdam and John P. O'Reardon of
the Department of Psychiatry in Penn's School of Medicine and Paula
R. Young, formerly of Penn's Department of Psychiatry.
The study was funded by the National Institute of Mental Health and
SmithKlineBeecham.
- VU

Steven
Hollon's online research bio
Richard
Shelton's online research bio
Robert
J. DeRubeis' home page
Clinical
research trial description
|